The benefit of MKK3 inhibitors over p38 inhibitors lacking specificity can be based on the fact that, in CRC, while p38δ has tumor promoter roles, p38α seems to be a tumor suppressor [89]. The gene discussed is MAP2K3; the disease is colorectal carcinoma.